Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Palisade BioPALI -0.29%33 3-Year EBITDA Growth Rate is 89.20% as of Jun. 2026, which is 8% above its 10-year median of 82.80. GuruFocus rates PALI with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,131 Biotechnology companies, Palisade Bio ranks better than 98.05% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 89.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 83.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Palisade Bio was 89.20% per year. The lowest was 78.00% per year. And the median was 82.80% per year.
Palisade Bio (NAS:PALI) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Palisade Bio 3-Year EBITDA Growth Rate Related Terms
PALI vs ABEO, RCKT, UPB: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Palisade Bio's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Palisade Bio 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Palisade Bio's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Palisade Bio's 3-Year EBITDA Growth Rate falls into.
Palisade Bio 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 89.20% mean?
Palisade Bio (PALI) has a 3-Year EBITDA Growth Rate of 89.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Palisade Bio and its competitors. This is near median its historical median of 82.80. Over the past decade, Palisade Bio's 3-Year EBITDA Growth Rate has ranged from 78.00 to 89.20. According to the industry distribution chart, Palisade Bio ranks #22 out of 1131 companies in the Biotechnology industry, placing it in the top 1.9%.
Is Palisade Bio's 3-Year EBITDA Growth Rate too high?
Palisade Bio's current 3-Year EBITDA Growth Rate of 89.20% is near median its 10-year median of 82.80. Over the past 10 years, this metric has ranged from a low of 78.00 to a high of 89.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Palisade Bio's value of 89.20% is 498.7% above this industry median. Based on the distribution chart, Palisade Bio ranks #22 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Palisade Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Palisade Bio's 3-Year EBITDA Growth Rate compare to ABEO and RCKT?
According to the Biotechnology industry distribution chart, Palisade Bio ranks #22 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Palisade Bio in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Palisade Bio's value of 89.20% is 498.7% above this benchmark. Historically, Palisade Bio's own 3-Year EBITDA Growth Rate has ranged from 78.00 to 89.20 over the past decade. While the company's 10-year median is 82.80 vs. the industry median of 14.90, Palisade Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Palisade Bio's current 3-Year EBITDA Growth Rate of 89.20% is 498.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Palisade Bio and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Palisade Bio's current 3-Year EBITDA Growth Rate is 89.20%, which is near median its own 10-year median of 82.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palisade Bio stock overvalued right now?
Palisade Bio (PALI) has a current 3-Year EBITDA Growth Rate of 89.20%. The current 3-Year EBITDA Growth Rate is 89.20%, which is near median its 10-year median of 82.80 and 498.7% above the Biotechnology industry median of 14.90. Palisade Bio's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Palisade Bio (PALI), the current 3-Year EBITDA Growth Rate is 89.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
33GF Score
Get the complete analysis for PALI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PALI has been successfully added to your 
